Holen Sie sich die Stockscreener-App
4.79
9.61%
0.42
Handel nachbörslich:
4.57
-0.22
-4.59%
Schlusskurs vom Vortag:
$4.37
Offen:
$4.12
24-Stunden-Volumen:
36,533
Relative Volume:
1.52
Marktkapitalisierung:
$2.87M
Einnahmen:
$10.48M
Nettoeinkommen (Verlust:
$-37.74M
KGV:
-0.296
EPS:
-16.1846
Netto-Cashflow:
$-29.03M
1W Leistung:
+0.63%
1M Leistung:
-66.79%
6M Leistung:
-85.15%
1J Leistung:
-96.20%
1-Tages-Spanne:
$4.02
$4.79
1-Wochen-Bereich:
$4.02
$4.9699
52-Wochen-Spanne:
$4.02
$540.00
Jaguar Health Inc Stock (JAGX) Company Profile
Firmenname
Jaguar Health Inc
Sektor
Branche
Telefon
415-371-8300
Adresse
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Vergleichen Sie JAGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
4.79 | 2.87M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer - ACCESS Newswire
Jaguar Animal Health Secures $3.448M in Private Placement - TipRanks
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials - ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Expands Workforce: New Stock Grants Signal Growth Strategy - Stock Titan
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health outlines key Q2 2025 catalysts for crofelemer programs - MSN
Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product - ACCESS Newswire
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health completes $3.4 million private placement By Investing.com - Investing.com South Africa
Jaguar Health completes $3.4 million private placement - Investing.com India
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Jaguar Health CEO Leads $3.4M Strategic Investment Ahead of Key 2025 Catalysts - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - Insider Monkey
Jaguar Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Jaguar Health Advances Plant-Based Pharmaceuticals - TipRanks
Jaguar Health’s Earnings Call: Growth Amid Challenges - TipRanks
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 - Investing.com Canada
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline By Investing.com - Investing.com South Africa
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline - Investing.com Australia
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 By Investing.com - Investing.com South Africa
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 - ACCESS Newswire
Jaguar Health, Inc. SEC 10-K Report - TradingView
StockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX) - Defense World
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey - Weatherford Democrat
Jaguar Health at Emerging Growth Virtual Conference: Strategic Catalysts Ahead - Investing.com
Jaguar Health CEO, board members and investors invest in $3.448M bridge financing - MSN
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study - ACCESS Newswire
Mytesi Shows Promising Results in Breast Cancer: FDA to Review Game-Changing Phase 3 Data - Stock Titan
Jaguar Health secures $3.448 million in convertible notes By Investing.com - Investing.com South Africa
Sector Update: Health Care - MarketScreener
Jaguar Health secures $3.448 million in convertible notes - Investing.com
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts - Corsicana Daily Sun
Jaguar Health Executives Invest in $3.5 Million Bridge Financing; Shares Fall - MarketScreener
Jaguar Health Management Backs Company with Personal Investment in $3.4M Financing Deal - Stock Titan
Upcoming Stock Splits This Week (March 24 to March 28) – Stay Invested - The Globe and Mail
JAGX stock touches 52-week low at $0.21 amid sharp annual decline - Investing.com Australia
JAGX stock touches 52-week low at $0.21 amid sharp annual decline By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Jaguar Health (NASDAQ:JAGX) Now Covered by StockNews.com - Defense World
Jaguar Health initiates reverse stock split to meet Nasdaq standards By Investing.com - Investing.com Canada
Jaguar Health falls as it announces reverse stock split - MSN
Jaguar Health to Implement 1-for-25 Reverse Stock Split -March 18, 2025 at 09:05 am EDT - Marketscreener.com
Jaguar Animal Health Announces Reverse Stock Split - TipRanks
Jaguar Health initiates reverse stock split to meet Nasdaq standards - Investing.com
Jaguar Health, Inc. Announces Reverse Stock Split - ACCESS Newswire
Jaguar Health's Major 1:25 Reverse Split: Critical Move for Nasdaq Compliance - StockTitan
Finanzdaten der Jaguar Health Inc-Aktie (JAGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):